Study title: Double-blind, randomized, multi-centre, crossover, placebo-controlled pilot study OXC is indicated for use in treatment of partial seizures in adults and pediatric patients ≥6 years of age. This is a pilot study to assess its efficacy in outpatient children and adoloscents with behavioural disorders
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Behavior and Behavior Mechanisms | |||||
Brands: Please see report, Please see report | |||||
MAH holders: Please see report, Please see report | |||||
Assessment: | |||||
Active substance: OXACARBAZEPINE | |||||
ATC code: N03AF02 | |||||
Document link: oxacarbazepine-TRI476BES04 Art45 Listing 2011.xls | |||||
Document date: 2011-09-22 | |||||
Study number: CTRI476BES04 | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | Y |